{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:56:47Z","timestamp":1782788207233,"version":"3.54.5"},"reference-count":136,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Center for Neurodegenerative Disorders (CENDIVE) at University Hospitals Cleveland","award":["R03AG086928"],"award-info":[{"award-number":["R03AG086928"]}]},{"name":"Center for Neurodegenerative Disorders (CENDIVE) at University Hospitals Cleveland","award":["3U24AG057437"],"award-info":[{"award-number":["3U24AG057437"]}]},{"name":"Awakening Angels Foundation","award":["R03AG086928"],"award-info":[{"award-number":["R03AG086928"]}]},{"name":"Awakening Angels Foundation","award":["3U24AG057437"],"award-info":[{"award-number":["3U24AG057437"]}]},{"name":"NIH","award":["R03AG086928"],"award-info":[{"award-number":["R03AG086928"]}]},{"name":"NIH","award":["3U24AG057437"],"award-info":[{"award-number":["3U24AG057437"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Down syndrome (DS) is a genetic disorder caused by an extra copy of chromosome 21 (trisomy 21 or T21) and is associated with an increased risk of early-onset Alzheimer\u2019s disease (AD), also known as DS-associated AD (DSAD). Individuals with DS typically develop amyloid neuropathology in their late-thirties to early-forties and the mean age of onset of clinical dementia is approximately 55 years. Recent advances in AD clinical research have focused on monoclonal antibodies (mAbs) targeting amyloid-\u03b2 (A\u03b2) plaques as a potential therapeutic approach. Therefore, there has been guarded enthusiasm about using anti-amyloid mAbs in the prevention\/treatment of DSAD. This narrative review and perspective explores the current understanding of amyloid pathology in AD and DSAD, the rationale for using anti-amyloid mAbs in the treatment of DSAD, and the challenges and opportunities for research toward the application of this therapeutic strategy to older adults with DS.<\/jats:p>","DOI":"10.3390\/brainsci14111084","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T06:29:57Z","timestamp":1730183397000},"page":"1084","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["On the Therapeutic Use of Monoclonal Antibodies Against Amyloid Plaques in Older Adults with Down Syndrome: A Narrative Review and Perspective"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7855-1190","authenticated-orcid":false,"given":"Alberto C. S.","family":"Costa","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Case Western Reserve University, Cleveland, OH 44106-6090, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrg1525","article-title":"Down syndrome and genetics\u2014A case of linked histories","volume":"6","author":"Patterson","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1002\/ajmg.a.38402","article-title":"Estimation of live birth and population prevalence of Down syndrome in nine U.S. states","volume":"173","author":"Buckley","year":"2017","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/bdr2.1589","article-title":"National population-based estimates for major birth defects, 2010\u20132014","volume":"111","author":"Mai","year":"2019","journal-title":"Birth Defects Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jar.12438","article-title":"50 years with Down syndrome: A longitudinal study","volume":"31","author":"Carr","year":"2018","journal-title":"J. Appl. Res. Intellect. Disabil."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Basten, I.A., Boada, R., Taylor, H.G., Koenig, K., Barrionuevo, V.L., Brandao, A.C., and Costa, A.C.S. (2018). On the Design of Broad-Based Neuropsychological Test Batteries to Assess the Cognitive Abilities of Individuals with Down Syndrome in the Context of Clinical Trials. Brain Sci., 8.","DOI":"10.3390\/brainsci8120205"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2990.1984.tb00351.x","article-title":"Alzheimer\u2019s presenile dementia, senile dementia of Alzheimer type and Down\u2019s syndrome in middle age form an age related continuum of pathological changes","volume":"10","author":"Mann","year":"1984","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1006\/exnr.1997.6777","article-title":"Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: A regional quantitative analysis","volume":"150","author":"Leverenz","year":"1998","journal-title":"Exp. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mrdd.20163","article-title":"Alzheimer\u2019s disease in Down syndrome: Neurobiology and risk","volume":"13","author":"Zigman","year":"2007","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3233\/JAD-170624","article-title":"Predictors of Age of Diagnosis and Survival of Alzheimer\u2019s Disease in Down Syndrome","volume":"61","author":"Sinai","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2435018","DOI":"10.1001\/jamanetworkopen.2024.35018","article-title":"Alzheimer Dementia among Individuals With Down Syndrome","volume":"7","author":"Rubenstein","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10072-010-0454-7","article-title":"Alzheimer and his disease: A brief history","volume":"32","author":"Cipriani","year":"2011","journal-title":"Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-2006-9S317","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis: An update and reappraisal","volume":"9","author":"Hardy","year":"2006","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00401-018-1918-8","article-title":"Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer\u2019s disease","volume":"136","author":"Morris","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1073\/pnas.82.24.8729","article-title":"Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related","volume":"82","author":"Wong","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","article-title":"Alzheimer\u2019s disease and Down\u2019s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein","volume":"122","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-beta Pathway in Alzheimer\u2019s Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/brain\/awad005","article-title":"Anti-amyloid antibody therapies in Alzheimer\u2019s disease","volume":"146","author":"Perneczky","year":"2023","journal-title":"Brain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3233\/JAD-230603","article-title":"Immunotherapy in Alzheimer\u2019s Disease: Current Status and Future Directions","volume":"101","author":"Vashisth","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JAD-240189","article-title":"Amyloid-Directed Antibodies: Past, Present, and Future","volume":"101","author":"Noorda","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chhabra, A., Solanki, S., Saravanabawan, P., Venkiteswaran, A., Nimmathota, N., and Modi, N.M. (Expert. Opin. Biol. Ther., 2024). A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer\u2019s disease, Expert. Opin. Biol. Ther., accepted.","DOI":"10.1080\/14712598.2024.2416947"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wang, Q., Chen, S., Wang, J., Shang, H., and Chen, X. (2024). Advancements in Pharmacological Treatment of Alzheimer\u2019s Disease: The Advent of Disease-Modifying Therapies (DMTs). Brain Sci., 14.","DOI":"10.3390\/brainsci14100990"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Twarowski, B., and Herbet, M. (2023). Inflammatory Processes in Alzheimer\u2019s Disease-Pathomechanism, Diagnosis and Treatment: A Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076518"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1474-4422(21)00215-5","article-title":"A contentious FDA ruling for Alzheimer\u2019s disease","volume":"20","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"q281","DOI":"10.1136\/bmj.q281","article-title":"Aduhelm: Biogen abandons Alzheimer\u2019s drug after controversial approval left it unfunded by Medicare","volume":"384","author":"Dyer","year":"2024","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/bmj.p1580","article-title":"Alzheimer\u2019s disease: Lecanemab gets full FDA approval and black box safety warning","volume":"382","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"q2010","DOI":"10.1136\/bmj.q2010","article-title":"Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer\u2019s drug","volume":"386","author":"Lenzer","year":"2024","journal-title":"BMJ"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-230099","article-title":"The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes","volume":"94","author":"Kepp","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"q1853","DOI":"10.1136\/bmj.q1853","article-title":"Lecanemab: Benefits of Alzheimer\u2019s drug are \u201cjust too small\u201d to justify cost, says NICE","volume":"386","author":"Kmietowicz","year":"2024","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"q1692","DOI":"10.1136\/bmj.q1692","article-title":"Lecanemab: European drug agency rejects Alzheimer\u2019s drug amid debate over efficacy and safety","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.arr.2020.101210","article-title":"The impact of aging in dementia: It is time to refocus attention on the main risk factor of dementia","volume":"65","author":"Mecocci","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/gerona\/glz180","article-title":"Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60\u2013102 Years","volume":"75","author":"Legdeur","year":"2020","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JAD-240406","article-title":"Beyond Amyloid-beta: Reevaluating Its Physiological Role to Find Safe Therapies Against Alzheimer\u2019s Disease","volume":"100","author":"Puzzo","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1523\/JNEUROSCI.3607-16.2017","article-title":"Amyloid-beta Peptide Is Needed for cGMP-Induced Long-Term Potentiation and Memory","volume":"37","author":"Palmeri","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/alz.13608","article-title":"Significance of a positive tau PET scan with a negative amyloid PET scan","volume":"20","author":"Robinson","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Qu, L., Xu, S., Lan, Z., Fang, S., Xu, Y., and Zhu, X. (2024). Apolipoprotein E in Alzheimer\u2019s Disease: Focus on Synaptic Function and Therapeutic Strategy. Mol. Neurobiol.","DOI":"10.1007\/s12035-024-04449-1"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"111181","DOI":"10.1016\/j.pscychresns.2020.111181","article-title":"Alzheimer\u2019s disease\u2014The \u2018microbial hypothesis\u2019 from a clinical and neuroimaging perspective","volume":"306","author":"Frolich","year":"2020","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Patro, S., Ratna, S., Yamamoto, H.A., Ebenezer, A.T., Ferguson, D.S., Kaur, A., McIntyre, B.C., Snow, R., and Solesio, M.E. (2021). ATP Synthase and Mitochondrial Bioenergetics Dysfunction in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011185"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101464","DOI":"10.1016\/j.arr.2021.101464","article-title":"Autophagy in Alzheimer\u2019s disease pathogenesis: Therapeutic potential and future perspectives","volume":"72","author":"Zhang","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/alz.13778","article-title":"Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome","volume":"20","author":"Hillerstrom","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00401-018-1866-3","article-title":"Patterns and severity of vascular amyloid in Alzheimer\u2019s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer\u2019s disease","volume":"136","author":"Mann","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"(2023). 2023 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/35012518","article-title":"The DNA sequence of human chromosome 21","volume":"405","author":"Hattori","year":"2000","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1126\/science.3810169","article-title":"Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer\u2019s disease","volume":"235","author":"Goldgaber","year":"1987","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1073\/pnas.90.5.2092","article-title":"Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells","volume":"90","author":"Busciglio","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/359322a0","article-title":"Amyloid beta-peptide is produced by cultured cells during normal metabolism","volume":"359","author":"Haass","year":"1992","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1439760","article-title":"Production of the Alzheimer amyloid beta protein by normal proteolytic processing","volume":"258","author":"Shoji","year":"1992","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/359325a0","article-title":"Isolation and quantification of soluble Alzheimer\u2019s beta-peptide from biological fluids","volume":"359","author":"Seubert","year":"1992","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0197-4580(02)00042-8","article-title":"Testing times for the \u201camyloid cascade hypothesis\u201d","volume":"23","author":"Hardy","year":"2002","journal-title":"Neurobiol. Aging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13195-023-01267-w","article-title":"Regional cerebral tau predicts decline in everyday functioning across the Alzheimer\u2019s disease spectrum","volume":"15","author":"Dubbelman","year":"2023","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimer\u2019s Dement"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u2019s Disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_57","first-page":"e12457","article-title":"A universal neocortical mask for Centiloid quantification","volume":"15","author":"Bourgeat","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Cogswell, P.M., Andrews, T.J., Barakos, J.A., Barkhof, F., Bash, S., Benayoun, M.D., Chiang, G.C., Franceschi, A.M., Jack, C.R., and Pillai, J.J. (2024). Alzheimer\u2019s Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for ARIA Monitoring. AJNR Am. J. Neuroradiol., ajnr.A8469.","DOI":"10.3174\/ajnr.A8469"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2114","DOI":"10.1212\/WNL.0000000000207156","article-title":"Accelerated Brain Volume Loss Caused by Anti-beta-Amyloid Drugs: A Systematic Review and Meta-analysis","volume":"100","author":"Alves","year":"2023","journal-title":"Neurology"},{"key":"ref_60","unstructured":"Weixel, N. (The Hill Nexstar, 2022). House Investigation Faults FDA Approval of Alzheimer\u2019s Drug Aduhelm as \u2018Rife with Irregularities\u2019, The Hill Nexstar."},{"key":"ref_61","unstructured":"Lin, G., Wright, A., Agboola, F., Herron-Smith, S., Pearson, S.D., and Rind, D.M. (2023). Beta-Amyloid Antibodies for Early Alzheimer\u2019s Disease: Effectiveness and Value, Institute for Clinical and Economic Review. Evidence Report."},{"key":"ref_62","unstructured":"Belluck, P. (The New York Times, 2024). New Drug Approved for Early Alzheimer\u2019s, The New York Times."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer\u2019s disease (AD2000): Randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp.2008.161703","article-title":"Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease","volume":"80","author":"Kasuga","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/brain\/awl237","article-title":"Phenotype associated with APP duplication in five families","volume":"129","author":"Cabrejo","year":"2006","journal-title":"Brain"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ng1718","article-title":"APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy","volume":"38","author":"Hannequin","year":"2006","journal-title":"Nat. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1093\/brain\/awl203","article-title":"APP duplication is sufficient to cause early onset Alzheimer\u2019s dementia with cerebral amyloid angiopathy","volume":"129","author":"Sleegers","year":"2006","journal-title":"Brain"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-160836","article-title":"Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer\u2019s Disease: The Role of APP","volume":"56","author":"Doran","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1352\/2008.46:215-228","article-title":"Successful aging in a 70-year-old man with down syndrome: A case study","volume":"46","author":"Devenny","year":"2008","journal-title":"Intellect. Dev. Disabil."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1352\/0047-6765(1997)035<0477:LOAWWD>2.0.CO;2","article-title":"Longevity of a woman with Down syndrome: A case study","volume":"35","author":"Chicoine","year":"1997","journal-title":"Ment. Retard."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1192\/bjp.162.5.711a","article-title":"Down\u2019s syndrome, longevity, and Alzheimer\u2019s disease","volume":"162","author":"Prasher","year":"1993","journal-title":"Br. J. Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Liou, J.J., Lou, J., Nakagiri, J., Yong, W., Hom, C.L., Doran, E.W., Totoiu, M., Lott, I., Mapstone, M., and Keator, D.B. (2024). A Neuropathology Case Report of a Woman with Down Syndrome who Remained Cognitively Stable. medRxiv.","DOI":"10.1101\/2024.06.01.24308050"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1352\/0895-8017(1998)103<0130:DIAWDS>2.0.CO;2","article-title":"Dementia in adults with Down syndrome: Diagnostic challenges","volume":"103","author":"Burt","year":"1998","journal-title":"Am. J. Ment. Retard."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1365-2788.2000.00305.x","article-title":"Sequence of cognitive decline in dementia in adults with Down\u2019s syndrome","volume":"44","author":"Devenny","year":"2000","journal-title":"J. Intellect. Disabil. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaneurol.2024.1612","article-title":"Tau Positron Emission Tomography for Predicting Dementia in Individuals with Mild Cognitive Impairment","volume":"81","author":"Groot","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","article-title":"The pattern of amyloid accumulation in the brains of adults with Down syndrome","volume":"12","author":"Annus","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/brain\/awu173","article-title":"Cognitive functioning in relation to brain amyloid-beta in healthy adults with Down syndrome","volume":"137","author":"Hartley","year":"2014","journal-title":"Brain"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/archneurol.2011.104","article-title":"Positron emission tomography of brain beta-amyloid and tau levels in adults with Down syndrome","volume":"68","author":"Nelson","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Rafii, M.S., Wishnek, H., Brewer, J.B., Donohue, M.C., Ness, S., Mobley, W.C., Aisen, P.S., and Rissman, R.A. (2015). The down syndrome biomarker initiative (DSBI) pilot: Proof of concept for deep phenotyping of Alzheimer\u2019s disease biomarkers in down syndrome. Front. Behav. Neurosci., 9.","DOI":"10.3389\/fnbeh.2015.00239"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0000000000001212","article-title":"Age dependence of brain beta-amyloid deposition in Down syndrome: An [18F]florbetaben PET study","volume":"84","author":"Jennings","year":"2015","journal-title":"Neurology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jalz.2015.05.013","article-title":"The effects of normal aging on amyloid-beta deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B","volume":"12","author":"Lao","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_84","first-page":"1","article-title":"Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population","volume":"9","author":"Lao","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jalz.2015.01.006","article-title":"Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer\u2019s dementia","volume":"11","author":"Sabbagh","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1474-4422(24)00084-X","article-title":"Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer\u2019s disease: A cross-sectional study","volume":"23","author":"Wisch","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jamaneurol.2022.1740","article-title":"Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers","volume":"79","author":"Janelidze","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Edwards, N.C., Lao, P.J., Alshikho, M.J., Ericsson, O.M., Rizvi, B., Petersen, M.E., O\u2019Bryant, S., Flores-Aguilar, L., Simoes, S., and Mapstone, M. (2023). Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome. medRxiv.","DOI":"10.1101\/2023.11.28.23298693"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Hendrix, J.A., Airey, D.C., Britton, A., Burke, A.D., Capone, G.T., Chavez, R., Chen, J., Chicoine, B., Costa, A.C.S., and Dage, J.L. (2021). Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer\u2019s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091907"},{"key":"ref_90","first-page":"e12582","article-title":"Cognitive and functional performance and plasma biomarkers of early Alzheimer\u2019s disease in Down syndrome","volume":"16","author":"Schworer","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamaneurol.2024.2579","article-title":"Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome","volume":"81","author":"Liu","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/brain\/awx057","article-title":"Biochemically-defined pools of amyloid-beta in sporadic Alzheimer\u2019s disease: Correlation with amyloid PET","volume":"140","author":"Roberts","year":"2017","journal-title":"Brain"},{"key":"ref_93","unstructured":"Writer, S. (2024, October 08). How Much Does a Single Grain of Rice Weigh?. Available online: https:\/\/www.reference.com\/world-view\/much-single-grain-rice-weigh-c39a20469d3fe660."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Fuller, J.P., Stavenhagen, J.B., and Teeling, J.L. (2014). New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer\u2019s Disease. Front. Neurosci., 8.","DOI":"10.3389\/fnins.2014.00235"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/psp4.12876","article-title":"Quantitative systems pharmacology model of the amyloid pathway in Alzheimer\u2019s disease: Insights into the therapeutic mechanisms of clinical candidates","volume":"12","author":"Ramakrishnan","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1212\/WNL.45.2.356","article-title":"Selective neuroanatomic abnormalities in Down\u2019s syndrome and their cognitive correlates: Evidence from MRI morphometry","volume":"45","author":"Raz","year":"1995","journal-title":"Neurology"},{"key":"ref_98","unstructured":"Newton, R.W., Marder, L., and Puri, S. (2015). Down Syndrome: Current Perspectives, Mac Keith Press."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2017.04.006","article-title":"Brain-predicted age in Down syndrome is associated with beta amyloid deposition and cognitive decline","volume":"56","author":"Cole","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1017\/S0033291709990985","article-title":"Brain anatomy and ageing in non-demented adults with Down\u2019s syndrome: An in vivo MRI study","volume":"40","author":"Beacher","year":"2010","journal-title":"Psychol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00005072-199009000-00006","article-title":"Small cerebral hemispheres in adults with Down\u2019s syndrome: Contributions of developmental arrest and lesions of Alzheimer\u2019s disease","volume":"49","year":"1990","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.trci.2016.02.004","article-title":"Dissociation of Down syndrome and Alzheimer\u2019s disease effects with imaging","volume":"2","author":"Matthews","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Ahmed, M.M., Johnson, N.R., Boyd, T.D., Coughlan, C., Chial, H.J., and Potter, H. (2021). Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.718426"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e12158","DOI":"10.1002\/trc2.12158","article-title":"Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer\u2019s disease","volume":"7","author":"Potter","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer\u2019s Disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMc1813435","article-title":"Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer\u2019s Disease","volume":"380","author":"Henley","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.neuro.23.1.649","article-title":"Synaptic plasticity and memory: An evaluation of the hypothesis","volume":"23","author":"Martin","year":"2000","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbr.2012.03.022","article-title":"Object recognition testing: Methodological considerations on exploration and discrimination measures","volume":"232","author":"Akkerman","year":"2012","journal-title":"Behav. Brain Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.neubiorev.2008.04.004","article-title":"Object recognition memory: Neurobiological mechanisms of encoding, consolidation and retrieval","volume":"32","author":"Winters","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_111","first-page":"9235796","article-title":"Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome","volume":"2018","author":"Roque","year":"2018","journal-title":"Neural Plast."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nn1860","article-title":"Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome","volume":"10","author":"Fernandez","year":"2007","journal-title":"Nat. Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3233\/JAD-171133","article-title":"Alzheimer\u2019s Amyloid-beta is an Antimicrobial Peptide: A Review of the Evidence","volume":"62","author":"Gosztyla","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jalz.2018.06.3040","article-title":"The antimicrobial protection hypothesis of Alzheimer\u2019s disease","volume":"14","author":"Moir","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Soscia, S.J., Kirby, J.E., Washicosky, K.J., Tucker, S.M., Ingelsson, M., Hyman, B., Burton, M.A., Goldstein, L.E., Duong, S., and Tanzi, R.E. (2010). The Alzheimer\u2019s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009505"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/nmt-2016-0035","article-title":"Alzheimer\u2019s disease: The potential therapeutic role of the natural antibiotic amyloid-beta peptide","volume":"6","author":"Kumar","year":"2016","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.0902-0055.2001.00100.x","article-title":"Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer\u2019s disease","volume":"17","author":"Riviere","year":"2002","journal-title":"Oral. Microbiol. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/mp200419b","article-title":"Antimicrobial properties of amyloid peptides","volume":"9","author":"Kagan","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3233\/JAD-121918","article-title":"Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer\u2019s disease brain tissue","volume":"36","author":"Poole","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Lathe, R., Sapronova, A., and Kotelevtsev, Y. (2014). Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature. BMC Geriatr., 14.","DOI":"10.1186\/1471-2318-14-36"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10875-020-00805-7","article-title":"Inborn Errors of Adaptive Immunity in Down Syndrome","volume":"40","author":"Verstegen","year":"2020","journal-title":"J. Clin. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Emes, D., Huls, A., Baumer, N., Dierssen, M., Puri, S., Russell, L., Sherman, S.L., Strydom, A., Bargagna, S., and Brandao, A.C. (2021). COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. J. Clin. Med., 10.","DOI":"10.1101\/2021.06.25.21259525"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"100769","DOI":"10.1016\/j.eclinm.2021.100769","article-title":"Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey","volume":"33","author":"Huls","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/path.2449","article-title":"Herpes simplex virus type 1 DNA is located within Alzheimer\u2019s disease amyloid plaques","volume":"217","author":"Wozniak","year":"2009","journal-title":"J. Pathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3233\/JAD-160451","article-title":"Bacterial Amyloid and DNA are Important Constituents of Senile Plaques: Further Evidence of the Spirochetal and Biofilm Nature of Senile Plaques","volume":"53","author":"Miklossy","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/11537510-000000000-00000","article-title":"Progressive multifocal leukoencephalopathy and newer biological agents","volume":"33","author":"Berger","year":"2010","journal-title":"Drug Saf."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3233\/JAD-231137","article-title":"Moving Towards Ethical-Practical Recommendations for Alzheimer\u2019s Disease Prediction: Addressing Interindividual, Interprofessional, and Societal Aspects","volume":"101","author":"Schicktanz","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3109\/09540261.2011.616189","article-title":"Transcranial magnetic stimulation, deep brain stimulation and personal identity: Ethical questions, and neuroethical approaches for medical practice","volume":"23","author":"Jotterand","year":"2011","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_129","first-page":"24","article-title":"The dignity of risk and the mentally retarded","volume":"10","author":"Perske","year":"1972","journal-title":"Ment. Retard."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14649365.2016.1257148","article-title":"Confessions of an inadequate researcher: Space and supervision in research with learning disabled children","volume":"18","year":"2017","journal-title":"Soc. Cult. Geogr."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13063-023-07221-3","article-title":"What do we talk about when we talk about \u201cequipoise\u201d? Stakeholder interviews assessing the use of equipoise in clinical research ethics","volume":"24","author":"Dewar","year":"2023","journal-title":"Trials"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/21507740.2022.2129858","article-title":"An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer\u2019s Disease","volume":"15","author":"Daly","year":"2024","journal-title":"AJOB Neurosci."},{"key":"ref_133","unstructured":"Biogen, E.I.A. (2024, October 06). Treat & Monitor: Initiate Treatment and Monitor for Safety. Available online: https:\/\/www.leqembihcp.com\/treat-and-monitor\/initiate-treatment."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"fcad074","DOI":"10.1093\/braincomms\/fcad074","article-title":"Association of biological sex with clinical outcomes and biomarkers of Alzheimer\u2019s disease in adults with Down syndrome","volume":"5","author":"Iulita","year":"2023","journal-title":"Brain Commun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/10600280231218253","article-title":"Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease","volume":"58","author":"Park","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/14\/11\/1084\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:23:06Z","timestamp":1760113386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/14\/11\/1084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":136,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["brainsci14111084"],"URL":"https:\/\/doi.org\/10.3390\/brainsci14111084","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}